Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus Gemcitabine in Advanced Urothelial Carcinoma
NCT00034593Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pemetrexed in transitional cell carcinoma of the urothelium (TCC), sponsored by Eli Lilly and Company. Status: completed.
02
Drugs
pemetrexed
03
Conditions
transitional cell carcinoma of the urothelium (TCC)
Beyond the preview
Go deeper on NCT00034593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034593.